Calithera Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Calithera Biosciences Inc (CALA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Calithera Biosciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 27M vs 448M combined for tracked competitors (5.7% combined share).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Calithera Biosciences Inc vs. its Competitors, Q4 2022
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Calithera Biosciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Calithera Biosciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Calithera Biosciences Inc's competitor groups requires a Commercial License.
Calithera Biosciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Calithera Biosciences Inc | - | - | - | Yes |
| Competitors combined (8) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CALA Stock Performance relative to its Competitors
CALA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Urogen Pharma Ltd | 282.9% | Outperformed |
| 2 | Crescent Biopharma Inc | 282.9% | Outperformed |
| 3 | Syndax Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Galectin Therapeutics Inc | 282.9% | Outperformed |
| 5 | Nymox Pharmaceutical Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Calithera Biosciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Calithera Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Calithera Biosciences Inc | 0.00 | 26.95 |
| Urogen Pharma Ltd | 2,042.91 | 188.32 |
| Syndax Pharmaceuticals Inc | 1,621.42 | 252.00 |
| Rapt Therapeutics Inc | 1,563.32 | 3.25 |
| Galectin Therapeutics Inc | 247.69 | - |
| Nymox Pharmaceutical Corporation | 18.73 | 0.01 |
| SUBTOTAL | 5,507.83 | 475.23 |
Sign in to see all competitors of Calithera Biosciences Inc .
Sources: Calithera Biosciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Calithera Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Calithera Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Rafael Holdings Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Calithera Biosciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Calithera Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Syndax Pharmaceuticals Inc | Biopharmaceutical Cancer Therapeutics 100.00 % |
| Crescent Biopharma Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Calithera Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Calithera Biosciences Inc | 0 | - | - |
| Urogen Pharma Ltd | 2,043 | 647,137 | -335,519 |
| Syndax Pharmaceuticals Inc | 1,621 | 845,651 | -740,822 |
| Rapt Therapeutics Inc | 1,563 | 77,357 | -2,515,167 |
| Galectin Therapeutics Inc | 248 | - | -3,093,667 |
| Nymox Pharmaceutical Corporation | 19 | 208 | -187,167 |
| PEERS TOTAL | 5,508 | 583,702 | -311,311 |
Sign in to see all peers for Calithera Biosciences Inc .
Calithera Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Calithera Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Calithera Biosciences Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 816, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,029,931 | 19.10 % |
| 2 | Johnson and Johnson | 643,198 | 11.93 % |
| 3 | Beone Medicines Ltd | 553,175 | 10.26 % |
| 4 | Abbvie Inc | 461,540 | 8.56 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Calithera Biosciences Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Calithera Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-29.
Calithera Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 0.5x | 4.5x | -4.0x |
| Return on Equity | -107.94 % | industry aggregate | -125.82 % |
| Return on Invested Capital | -82.68 % | -2.85 % (avg) | -79.83 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Calithera Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | -33.35 % | -20.46 % | -35.51 % | -36.05 % | -81.09 % | -82.68 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Calithera Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 816 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Calithera Biosciences Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Calithera Biosciences Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Calithera Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 125.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-82.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Calithera Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Calithera Biosciences Inc | 3.96 | 4.10 | - |
| Urogen Pharma Ltd | 2.08 | 4.11 | - |
| Syndax Pharmaceuticals Inc | 1.71 | 5.25 | 2.48 |
| Rapt Therapeutics Inc | 3.71 | 9.02 | - |
| Galectin Therapeutics Inc | 0.19 | 0.21 | - |
| Nymox Pharmaceutical Corporation | 0.01 | 0.09 | - |
Sign in to see all peers for Calithera Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Calithera Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Calithera Biosciences Inc | Q4 2022 | - | - |
| Urogen Pharma Ltd | Q2 2026 | +206.2 % | - |
| Syndax Pharmaceuticals Inc | Q2 2026 | +91.8 % | - |
| Rapt Therapeutics Inc | Q3 2025 | - | - |
| Galectin Therapeutics Inc | Q2 2026 | - | - |
| Nymox Pharmaceutical Corporation | Q4 2024 | - | - |
| PEERS TOTAL | +135.5 % | - |
Sign in to see all peers for Calithera Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Calithera Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Calithera Biosciences Inc | Q4 2022 | - | -41.0 % |
| Urogen Pharma Ltd | Q2 2026 | +85.1 % | -57.4 % |
| Syndax Pharmaceuticals Inc | Q2 2026 | - | - |
| Rapt Therapeutics Inc | Q3 2025 | - | - |
| Galectin Therapeutics Inc | Q2 2026 | - | - |
| Nymox Pharmaceutical Corporation | Q4 2024 | - | - |
Sign in to see all peers for Calithera Biosciences Inc .
Calithera Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Calithera Biosciences Inc | - | - | - |
| Urogen Pharma Ltd | - | - | - |
| Syndax Pharmaceuticals Inc | - | - | - |
| Rapt Therapeutics Inc | - | - | - |
| Galectin Therapeutics Inc | - | - | - |
| Nymox Pharmaceutical Corporation | - | - | - |
Sign in to see all peers for Calithera Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Calithera Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Calithera Biosciences Inc | - | 0.00 |
| Urogen Pharma Ltd | - | 10.85 |
| Syndax Pharmaceuticals Inc | - | 6.43 |
| Rapt Therapeutics Inc | - | 481.17 |
| Galectin Therapeutics Inc | - | - |
| Nymox Pharmaceutical Corporation | - | 3,746.84 |
| PEERS AVERAGE | - | 11.59 |
Sign in to see all peers for Calithera Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.